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AbstrAct
Valosin containing protein (p97) is a chaperone implicated in a large number 
of biological processes including endoplasmic reticulum (ER)-associated protein 
degradation and autophagy. Silencing of p97 in rheumatoid arthritis (RA) synovial 
fibroblasts (RASFs) increased the amount of polyubiquitinated proteins, whereas 
silencing of its interaction partner histone deacetylase 6 (HDAC6) had no effect. 
Furthermore, silencing of p97 in RASFs increased not only rates of apoptotic cell 
death induced by TRAIL but also induced an autophagy-associated cell death during 
ER stress that was accompanied by the formation of polyubiquitinated protein 
aggregates and large vacuoles. Finally, we demonstrated an anti-arthritic effect of 
siRNAs targeting p97 in collagen-induced arthritis in rats. Our data indicate that p97 
may be a new potential target in the treatment of RA. 
INtrODUctION
Rheumatoid arthritis (RA) is characterized by 
chronic joint inflammation and progressive destruction of 
cartilage and bone which leads to severe joint pain and 
ultimately loss of function. Joint-resident RA synovial 
fibroblasts (RASFs) play a pivotal role in the pathogenesis 
of RA. RASFs are capable of producing a large set 
of inflammatory cytokines, chemokines and matrix-
degrading enzymes and thereby actively contribute to the 
inflammatory and joint destructive state in RA [1]. Since 
RASFs produce large amounts of proteins it was estimated 
that as much as 30% of newly synthesized proteins are 
misfolded [2]. The continuous removal of misfolded 
proteins is therefore essential for cell homeostasis. 
The ATPase valosin containing protein (p97/
VCP) is a chaperone implicated in a large number of 
biological processes including endoplasmic reticulum 
(ER) associated degradation [3], macroautophagy 
(hereafter referred to as autophagy) [4], and cell cycle 
regulation [5]. Owing to its role in protein quality 
control and cell survival, p97 has also been implicated 
as a potential therapeutic target in cancer [5, 6]. Histone 
deacetylase 6 (HDAC6) is an unique member of HDACs 
since it is not only present in the nucleus but it is also 
localized in the cytoplasm where it deacetylases non-
histone substrates such as microtubules [7]. Also HDAC6 
contributes to the cellular protein quality control by 
binding polyubiquitinated misfolded proteins, modifying 
the dynamics of microtubules, and finally delivering 
the misfolded proteins along the microtubules to 
autophagosomes for degradation [8]. p97 and HDAC6 
have been shown to interact with each other [9, 10] and 
a finely tuned balance of these proteins was suggested to 
determine the fate of misfolded proteins in embryonic and 
3T3 fibroblasts. An imbalance of a p97-HDAC6 molar 
ratio in favor of HDAC6 was described to enhance the 
formation of ubiquitin protein aggregates, whereas p97 
promotes protein degradation [9]. Here, we describe the 
role of a p97-controlled polyubiquitin turnover in cell 
death pathways in RASFs and the beneficial effects of p97 
inhibition in an in vivo arthritis model.
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rEsULts
the expression of p97 and the expression of 
HDAc6 in rAsFs and OAsFs 
Since both p97 and HDAC6 control the fate of 
misfolded proteins [9], we first evaluated the expression 
levels of p97 and HDAC6 by immunohistochemistry 
in synovial tissues obtained from RA and osteoarthritis 
(OA) patients, as well as by Western blotting and Real-
time PCR in cultured synovial fibroblasts (RASFs and 
OASFs). Staining of p97 and HDAC6 was restricted to 
the lining layer and vessels of synovial tissues and was 
similarly detected in RA and OA patients (Figure 1A, 1B). 
Consistent with this, p97 and HDAC6 proteins in cultured 
synovial fibroblasts reached equal levels in RA and OA 
patients (Figure 1C–1E). Interestingly, the expression 
levels of p97 and HDAC6 in RASFs and OASFs 
positively correlated at both protein (Figure 1F) and 
mRNA (Figure 1G) levels, suggesting the presence of a 
co-regulating factor.
p97, HDAc6 and polyubiquitinated protein 
interactions in rAsFs 
Having observed that p97 and HDAC6 levels are 
also balanced in RASFs as it was previously shown 
for other fibroblast types [9], we next evaluated the 
interaction between p97, HDAC6 and polyubiquitinated 
proteins. Using proximity ligation assays, we detected 
intracellular interactions of p97 with HDAC6, HDAC6 
with polyubiquitin and p97 with polyubiquitin in RASFs 
(Figure 2A). The siRNA-mediated knockdown of p97 did 
not affect HDAC6 mRNA and protein levels, and vice 
versa silencing of HDAC6 did not affect levels of p97 
(Figure 2B, 2C). Silencing of p97 in RASFs induced the 
accumulation of lysine 48 (K48)-conjugated (Figure 2C) 
but not lysine 63 (K63)-conjugated polyubiquitinated 
proteins (data not shown). On the other hand, silencing of 
HDAC6 did not alter levels of polyubiquitinated proteins 
in RASFs. Knockdown of p97 or HDAC6 did not affect 
the induction of autophagy monitored by LC3 conversion 
(Figure 2D). Since interfering with p97 expression levels 
in RASFs was sufficient to increase levels of protein 
poly-ubiquitination without further stimulation, we 
concentrated in the following experiments on the function 
of p97 in RASFs.
p97 protects rAsF from trAIL-induced 
apoptotic cell death 
We have previously shown that the accumulation of 
polyubiquitinated proteins in RASFs leads to the induction 
of cell death pathways [11]. Given that p97 plays a critical 
role in polyubiquitin turnover, we hypothesized that p97 
might have a protective role in induction of cell death 
pathways in RASFs. The siRNA mediated silencing of 
p97 increased TRAIL-induced annexin V- or PI-positive 
cells by 74 ± 4% (mean ± SD) compared to control siRNA 
transfected cells (Figure 3A, 3B). This was accompanied 
by caspase-3 activation (Figure 3C, 3D), indicating a 
protective role of p97 against apoptotic cell death in 
RASFs. Knockdown of p97 did not increase spontaneous 
annexin V- or PI-positive RASFs (Figure 3A). 
p97 protects rAsFs from Er stress-induced 
autophagy-associated cell death 
We have recently described that RASFs are, 
compared to OASFs, hypersensitive to a non-apoptotic, 
autophagy-associated cell death under conditions of severe 
ER stress, leading to a massive cytoplasmic vacuolization 
and the formation of polyubiquitinated protein aggregates 
[11]. In order to analyze a potential role of p97 in an 
autophagy-associated cell death induction in RASFs, 
we inhibited p97 in RASFs by siRNA transfection or 
treatment with the p97 inhibitor DBeQ, followed by a 
treatment with the ER stress inducer TG (5 µM), in the 
presence or absence of the autophagy inhibitor 3-MA. 
Both silencing (Figure 4A, 4B) and inhibition of p97 
by DBeQ treatment (Supplementary Figure S1A, S1B) 
enhanced the cytoplasmic vacuolization and increased the 
amount of annexin V- or PI-positive cells. These effects 
were inhibited by treatment with the autophagy inhibitor 
3-MA (Figure 4A, 4B, Supplementary Figure S1A, S1B). 
Furthermore, silencing and inhibition of p97 
resulted in increased formation of ER-stress-induced 
polyubiquitinated protein aggregates (Figure 4C, 4D), and 
3-MA treatment reduced the intensity of polyubiquitin 
staining in DBeQ treated cells during ER stress 
(Supplementary Figure S1C). These results point to a 
protective role of p97, not only against an apoptotic cell 
death but also against the autophagy-associated cell death 
in RASFs. Since 5 µM of TG used in previous experiments 
induces very severe ER stress in RASFs [11], we also 
evaluated the role of p97 under conditions of a less severe 
ER stress induced by smaller doses of TG (5 to 500 nM). 
Treatment of RASFs with the p97 inhibitor DBeQ and TG 
concentrations as low as 50 nM were sufficient to induce 
a cytoplasmic vacuolization (Supplementary Figure S1D) 
and the formation of polyubiquitinated protein aggregates 
(Supplementary Figure S1E, S1F). These effects were not 
observed in the absence of DBeQ. These results indicate 
that the inhibition of p97 boosts ER stress-induced cell 
damage from tolerable to intolerable levels in RASFs.
the role of p97 in arthritis and proliferation of 
synovial fibroblasts in vivo 
In order to evaluate the role of p97 in synovial 
tissues in vivo, we induced collagen-induced arthritis 
(CIA) in Lewis rats followed by an intra-articular injection 
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Figure 1: Expression of p97 and HDAC6 in synovial tissues and synovial fibroblasts. Representative staining of synovial 
tissues from OA and RA patients with anti-p97 antibodies (A) and anti-HDAC6 antibodies (b). Original magnification ×100. Expression 
of p97 and HDAC6 in OASFs and RASFs, as determined by Western blotting (c). Quantification of Western blot results (D, E). Values 
are the mean ± SD. Correlation of p97 and HDAC6 expression at protein levels (F), as determined by Western blotting, and mRNA levels 
(G), as determined by quantitative reverse transcription–polymerase chain reaction analysis. 
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of siRNAs targeting p97 or control siRNAs. To evaluate 
proliferation rates of synovial fibroblasts, rat synovial 
tissues were immunolabeled with Hsp47 [12]. The 
efficiency of p97 siRNAs was evaluated in CIA tissues 
obtained from knee and ankle joints three days after the 
injection of siRNAs into ankle joints. Western blotting 
revealed a sufficient knockdown of p97 in ankle joints, 
whereas p97 levels in non-injected knees were not affected 
(Figure 5A). Serum levels of antibodies against type II 
collagen were similar in the control siRNA group and the 
p97 siRNA group (Figure 5B). The intra-articular injection 
of p97 siRNAs, compared to control siRNAs, significantly 
suppressed arthritis scores (Figure 5C, 5D), grades of 
bone erosion (Figure 5E, 5F) and cartilage destruction 
(Figure 5G, 5H), and the Hsp47-positive fractional area in 
synovial tissues (Figure 5I, 5J) of ankle joints. 
Figure 2: Intracellular interaction among p97, HDAc6 and polyubiquitinated proteins and the effect of silencing 
of p97 or HDAC6 on the expression of their interacting partners in RASFs. Cells were fixed, incubated with anti-p97, 
anti-HDAC6 and anti-polyubiquitin (K48) antibodies and applied to in situ proximity ligation assay (red), followed by DAPI staining 
(blue) (A). Cells were transfected with siRNAs targeting p97 (p97#1, p97#2), HDAC6 or control siRNAs (0.5 µM siRNA to 2.5 × 105 
cells). Expression levels of p97 and HDAC6 mRNA were analyzed 48 hours after transfection by quantitative Real-time PCR using HPRT1 
as endogenous control (b). Expression levels of polyubiquitinated (K48 conjugated) proteins, HDAC6, and p97 (c) and the induction of 
autophagy monitored by LC3-II/I conversion (D) 48 hours after the transfection were determined by Western blotting. Expression levels of 
α-tubulin were used as endogenous control. 
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DIscUssION
Continuous removal of misfolded proteins by the 
ubiquitin-proteasome system and the autophagy-lysosome 
pathway is essential for the survival of cells [13]. 
A key function of p97 is to maintain protein homeostasis 
through a network of protein quality processes. A large 
collection of p97-interacting proteins has been identified 
through proteomic studies [14]. Among those, HDAC6 
was described to not only interact with p97 but also to 
interact with polyubiquitinated chains [9]. We were able to 
verify that these interactions also occur in RASFs. Both, 
p97 and HDAC6 play an essential role in the removal of 
misfolded proteins. Whereas p97 is thought to facilitate the 
ubiquitin-proteasome dependent degradation of misfolded 
proteins, HDAC6 delivers them along microtubules 
to autophagosomes for degradation. Beside the direct 
interaction of p97 and HDAC6 a counteracting role of 
these molecules was described interfering with the ability 
of their partner to interact with ubiquitin [9]. Consistent 
with previous reports in other fibroblasts [9], we showed 
a fine balance between p97 and HDAC6 expression levels 
in RASFs. We identified p97 as a critical component in 
controlling the polyubiquitin turnover in RASFs. Whereas 
silencing of p97 in RASFs was sufficient to increase levels 
of polyubiquitinated proteins without a further stimulation, 
Figure 3: The protective role of p97 in TRAIL-induced apoptosis in RASFs. Cells were transfected with siRNAs targeting 
p97 or control siRNAs (0.5 µM siRNA to 2.5 × 105 cells) and treated with 100 ng/ml TRAIL for 24 hours. Dead cells were evaluated 
microscopically (original magnification ×100), by flow cytometry using annexin V/propidium iodide (PI) staining (A, b), and by a caspase-3 
activity assay (c, D). ** = p < 0.01.
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Figure 4: Effects of p97 inhibition on cell death and formation of polyubiquitinated protein aggregates and vacuoles 
in RASFs under conditions of endoplasmic reticulum stress. Cells were transfected with siRNA targeting p97 or control 
siRNA (0.5 µM siRNA to 2.5 × 105 cells) and then treated for 72 hours with 5 µM thapsigargin (TG) in presence or absence of 5 mM 
3-methyladenine (3-MA). Dead cells were evaluated microscopically (original magnification x100) and by flow cytometry using annexin 
V/propidium iodide (PI) staining. Numbers in each compartment are the percentage of cells (A, b). Cells were treated as above (in absence 
of 3-MA), fixed and stained with anti-ubiquitin antibodies (green) and DAPI (blue). Original magnification ×400 (c). Ubiquitin-positive 
dots per cell were calculated with a software (D). * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
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Figure 5: Effects of p97 inhibition in an in vivo arthritis model. CIA was induced in 7-week-old Lewis rats. Scrambled or p97 
siRNA (10 µM)-atelocollagen complexes were injected into ankle joints of rats 14 days after the first immunization with type II collagen 
(day 15). The siRNA-mediated knockdown of p97 in collagen-induced arthritis (CIA) rat synovial tissues obtained from knee and ankle 
joints three days after the injection of siRNA into ankle joints was verified by Western blotting (A).  Serum levels of antibodies against 
type II collagen on the day of sacrifice (day 29) (b). Representative pictures of the ankle joints on day 22 (c). Arthritis score following 
the induction of CIA (D). Bone erosion was assessed by micro-CT on day 29. Cor., coronal; Sag., sagittal. (E, F). Hematoxylin and Eosin 
staining of the ankle joints (G). Cartilage destruction was quantified histologically (H). Hsp47 was labelled to evaluate the proliferation of 
fibroblasts in synovial tissues. Original magnification ×100. Values are the mean ± SD (I, J). * = p < 0.05; ** = p < 0.01.
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silencing of HDAC6 had no effect. To date, few studies 
have shown the efficacy of HDAC6 inhibitors in arthritis 
models in vivo [15, 16], however, the effects are likely not 
related to the HDAC6 function in protein turnover. 
p97 was shown to have both pro- and anti-
apoptotic roles but its role in synovial tissues has not been 
investigated yet. On the one hand, p97 is involved in the 
processing of caspase-9 [17]. Conversely, several pro-
apoptotic genes are upregulated following knockdown of 
p97 [18]. In addition, p97 activates NFκB by dissociating 
its inhibitor IκBα, resulting in increased expression 
levels of anti-apoptotic genes [19]. An impaired ER-
associated protein degradation caused by p97 inhibition 
can also trigger apoptosis [20]. The anti-apoptotic roles 
of p97 are most relevant for the cell loss in inclusion body 
myopathy with Paget’s disease of bone and frontotemporal 
dementia which is caused by mutations in the p97 gene 
[21]. In RA, the apoptosis-resistant phenotype of RASFs 
has been linked closely to the progressive destruction to 
articular cartilage and hallmarks synovial cell activation 
and contributes to chronic inflammation and hyperplasia 
[22]. A number of molecules have been shown to account 
for the apoptosis-resistant phenotype of RASFs [23–30] 
and our data indicate that also p97 fulfills a protective 
role against a TRAIL-induced apoptotic cell death in 
RASFs. Our immunohistochemical analysis showed not 
only high levels of p97 in the synovial lining but also 
significant expression levels of p97 in vessels of synovial 
tissues. High endothelial levels of p97 were previously 
also shown in diverse types of cancers [31], however, 
the endothelial function of p97 has not been studied yet. 
A proteomic study on cultured, apoptotic human umbilical 
vein endothelial cells identified decreased expression 
levels of p97 and suggested an anti-apoptotic role of p97 
also in the vascular endothelium [32]. The p97 inhibitor 
DBeQ was shown to rapidly activate caspase-3/7 in HeLa 
cells but it is not clear whether this is a specific effect of 
p97 inhibition or an off-target effect of this compound 
[33]. In our study, the treatment of RASFs with DBeQ 
resulted in increased cell death rates (data not shown), 
while the siRNA-mediated knockdown of p97 did not 
increase spontaneous cell death (Figure 3A), indicating an 
off-target pro-apoptotic effect of DBeQ in RASFs. 
Beside the anti-apoptotic role of p97 in RASFs, we also 
identified a protective role of p97 in an autophagy-associated 
cell death in these cells. Although autophagy constitutes a 
cytoprotective response activated by cells to cope with 
stress and is rather protective of cell death, induction of 
autophagy also leads to cell death under certain conditions 
[34]. Autophagy-associated cell death, also called autophagic 
cell death, is defined as cell death that is accompanied by 
a massive cytoplasmic vacuolization and which can be 
suppressed by the inhibition of the autophagic pathway 
by chemicals or genetic means [35]. We have previously 
described a hypersensitivity to autophagy-associated cell 
death under conditions of severe ER stress induced by 5 µM 
TG in RASFs compared to OASFs [11]. The precise 
molecular mechanisms regulating this autophagy-associated 
cell death in RASFs are incompletely understood. p97 has 
been shown to play an essential role in the maturation of 
autophagosomes in the late stage of autophagy [4, 36] and 
an impaired maturation of autophagosome might activate 
autophagy-associated cell death. In RASFs, the inhibition of 
autophagy by 3-MA reduced levels of cell death induced by 
p97 silencing and inhibition.
Molecular targets interfering with cell death 
pathways are potential therapeutic targets in cancer and p97 
inhibitors have promising anti-cancer effects [14]. Our data 
provide evidence for beneficial effects of interfering with 
cell death pathways in RASFs and in CIA in vivo by the 
inhibition of p97. p97 exhibited a critical role compared to 
HDAC6 in terms of promoting the polyubiquitin turnover 
in RASFs. The inhibition of p97 promoted not only a 
TRAIL-induced apoptotic cell death but also the ER stress-
induced autophagy-associated cell death in RASFs and 
suppressed CIA and proliferation of synovial fibroblasts 
in vivo. p97, as in the treatment of cancer, is expected to be 
a potential therapeutic target for RA through the regulation 
of polyubiquitin turnover and cell death pathways in 
synovial fibroblasts, key players in the pathogenesis of RA.
MAtErIALs AND MEtHODs
Patient samples and cell preparation
Synovial fibroblasts were derived from synovial 
tissue specimens that were obtained from RA and OA 
patients during joint replacement surgery (Department 
of Orthopedic Surgery, Schulthess Clinic, Zurich, 
Switzerland). All RA patients fulfilled the American 
College of Rheumatology criteria for classification of the 
disease [37] and all patients provided informed consent. 
Cells were cultured as described elsewhere [38] and used 
between passages 4 to 8 for all experiments.
Immunohistochemistry for human synovial 
tissues
After deparaffinization, tissue sections of RA and 
OA patients were pre-treated with citrate buffer (10 mM 
sodium citrate, pH 6.0). Endogenous peroxidase activity 




. Nonspecific protein binding 
was blocked with 1% bovine serum albumin/ 5% goat 
serum for 40 minutes. Mouse monoclonal anti-p97 
antibodies (Abcam), mouse monoclonal anti-HDAC6 
antibodies (Santa Cruz) or mouse IgG2a (isotype control) 
were applied over night at 4°C. Slides were washed in 
PBS-T (0.05% Tween 20 in PBS) and incubated with 
biotinylated goat anti-mouse antibodies (1:1000; Jackson 
ImmunoResearch). The signal was amplified with 




To induce cell death, cells were treated with 100 ng/ml 
tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand (TRAIL; R&D Systems) for 24 hours or 5 nM to 
5 µM of the ER stress inducer thapsigargin (TG; Enzo 
Life Sciences) for 72 hours in the presence or absence 
of 5 mM of the autophagy inhibitor 3-methyladenine 
(3-MA; Enzo Life Sciences). Where indicated, cells were 
treated with 5 µM of the selective p97 inhibitor N2,N4-
dibenzylquinazoline-2,4-diamine (DBeQ; Sigma-Aldrich) 
[33]. Controls were treated with matched amounts 
of DMSO. 
transfection of rAsFs
2.5 × 105 cells were transfected with 0.5 µM siRNA 
targeting p97 (Qiagen) or HDAC6 (Qiagen) or scrambled 
siRNAs as a control using the Amaxa Basic Nucleofector 
Kit for Primary Mammalian Fibroblasts (Lonza). 48 hours 
after transfection cells were treated as indicated and then 
harvested for Western blotting, RNA isolation or flow 
cytometry. Knockdown of p97 and HDAC6 was verified 
by Western blotting.
Western blotting
Cells were lysed in Laemmli buffer (62.5 mM 
TrisHCl, 2% SDS, 10% Glycerol, 0.1% Bromphenolblue, 
5 mM β-mercaptoethanol). Whole cell lysates were 
separated on 10% SDS polyacrylamide gels and electro 
blotted onto nitrocellulose membranes (Whatman). 
Membranes were blocked for 1 hour in 5% (w/v) non-
fat milk in TBS-T (20 mM Tris base, 137 mM sodium 
chloride, 0.1% Tween 20, pH 7.6). The membranes were 
probed with antibodies against p97 (Abcam), HDAC6 
(Cell Signaling), ubiquitin Lys48 (Merck), ubiquitin Lys63 
(Millipore), LC3B (Cell Signaling) or α-tubulin (Abcam) 
as an endogenous control. As secondary antibodies, 
horseradish peroxidase-conjugated goat anti-rabbit or 
goat anti-mouse antibodies (Jackson ImmunoResearch) 
were used. Signals were detected using the ECL Western 
blotting detection reagents (GE Healthcare) and the Alpha 
Imager Software system (Alpha Innotech). Expression 
analysis of specific proteins was performed by pixel 
quantification of the electronic image.
real-time polymerase chain reaction (Pcr)
Total RNA was isolated from cells using the 
ReliaPrep RNA Cell Miniprep System (Promega) 
including on column DNase I (Promega) digest and 
reversed transcribed. Real-time PCR was performed using 
SYBR green (Applied Biosystems) and primers specific for 
p97 and HDAC6. The primer sequences were as follows: 
p97 forward, 5′- AGCTGCTCACCATGTGGTTTGGG-3′; 
p97 reverse, 5′- CAGCTTGGCGGGCCTTGTCA-3′; 
HDAC6 forward, 5′- GAAAGTCACCTCGGCATCAT-3′; 
HDAC6 reverse, 5′- TAGTCTGGCCTGGAGTGGAC-3′. 
Constitutively expressed human glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and hypoxanthin 
guanin phosphoribosyltransferase (HPRT1) were 
measured for internal standard sample normalization using 
primers as described elsewhere [39]. Relative mRNA 
expression levels were calculated by the comparative 
threshold cycle method (∆Ct and ∆∆Ct).
Analysis of cell death
After treatment, cells were detached with trypsin, 
washed twice with PBS, and resuspended in annexin V 
binding buffer (BD Biosciences) at a concentration of 
1 × 106 cells/ ml. Next, cells were incubated with FITC 
annexin V (BD Biosciences) and propidium iodide 
(PI, Sigma-Aldrich) for 15 minutes at room temperature in 
the dark, and analyzed by flow cytometry (FACSCalibur, 
BD Biosciences).
Analysis of caspase-3 activity
Following treatment, cells were detached with 
trypsin, resuspended in cell culture medium at a 
concentration of 1 × 106 cells/ ml and incubated with 
caspase-3 substrate (NucView 488, Biotium) for 
20 minutes at room temperature in the dark. Caspase-3 
activity was analyzed by flow cytometry (FACSCalibur).
Immunocytochemistry
Cells were cultured in chamber slides (Lab-Tek, Nunc), 
fixed with 4% paraformaldehyde and permeabilized 
with TBS containing 0.1% Triton X-100. Non-specific 
binding was blocked with 1% bovine serum albumin/ 
5% goat serum for 40 minutes. Slides were incubated 
with anti-ubiquitin Lys48 antibodies overnight at 4°C. 
After washing, slides were incubated with FITC–
conjugated secondary antibodies (Thermo Scientific) 
for 30 minutes and nuclei were stained with DAPI 
(Sigma-Aldrich). Slides were covered with fluorescent 
mounting medium (Dako) and analyzed with a fluorescence 
microscope (Axio Imager, Carl Zeiss). Ubiquitin-positive 
dots per cell were calculated with a software (Hybrid Cell 
Count, Keyence).
Proximity ligation assays
Intracellular protein interactions were analyzed 
using the Duolink® kit (Olink Bioscience) which is based 
on the use of two unique and bi-functional probes called 
PLA™. Each probe consists of a secondary antibody 
attached to a unique synthetic oligonucleotide that acts as a 
reporter. Cells were cultured in chamber slides (Lab-Tek), 
fixed with 4% paraformaldehyde and permeabilized with 
TBS containing 0.1% Triton X-100. Non-specific binding 
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was blocked with 1% bovine serum albumin/ 5% goat 
serum for 40 minutes. Slides were incubated with two 
primary antibodies overnight at 4°C. After washing, slides 
were incubated with the secondary oligonucleotide-linked 
antibodies provided in the kit. The oligonucleotides bound 
to the antibodies were hybridized, ligated, amplified, and 
detected using a fluorescent probe provided in the kit 
and nuclei were stained with DAPI. Slides were covered 
with fluorescent mounting medium and analyzed with a 
fluorescence microscope (Axio Imager).
Induction of collagen-induced arthritis (cIA) 
and administration of sirNA in rats
CIA was induced in six 7-week-old female Lewis rats 
by immunizing 200 ml solution of 1 mg/ml porcine type II 
collagen (Chondrex) dissolved in 0.05 M acetic acid and 
emulsified in incomplete Freund’s adjuvant (Chondrex) at 
the base of the tail [40]. Seven days later, the rats received 
a booster immunization with the collagen. On day 15, the 
rats received an intra-articular injection, into both right and 
left ankles, of a 50 μl solution containing 10 µM siRNA–
atelocollagen (Koken) complexes targeting p97 (Qiagen) 
or control. Silencing efficiency of p97 siRNAs was 
evaluated by Western blotting in in CIA tissues obtained 
from knee and ankle joints three days after the injection 
of siRNAs into ankle joints. On days 1, 8, 15, 18, 22, 26 
and 29, arthritis was scored according to paw thickness and 
ankle diameter from 0 (neither erythema nor swelling) to 4 
(erythema and severe swelling that encompassed the ankle, 
foot, and digits or ankylosis of the limb) [41]. Bone erosion 
of each ankle joint was scored in a blinded manner on day 
29 by micro–computed tomography (micro-CT) (R_mCT2, 
Rigaku) from 0 (normal joint) to 3 (severe cartilage and 
bone erosions) [42]. The experimental protocol was 
approved by the Animal Ethics Committee at Hokkaido 
University.
ELIsA for anti-type II collagen antibodies in rat 
sera
Blood samples were collected from rats on day 29. 
Serum level of anti-type II collagen IgG was detected by 
enzyme-linked immunosorbent assay (Chondrex).
Immunohistochemistry for rat synovial tissues
Rats were sacrificed on day 29 for 
immunohistochemical analyses. The ankles were decalcified 
and embedded in paraffin. After deparaffinization, the 
tissue sections were pre-treated with citrate buffer (pH 6.0) 
for 40 minutes at 80°C. Endogenous peroxidase activity 




 in methanol. Nonspecific 
protein binding was blocked with G-Block (Genostaff) for 
10 minutes. Endogenous biotin, biotin receptors, and avidin 
binding sites were blocked with the avidin/biotin blocking 
kit (SP-2001, Vector Laboratories). Mouse monoclonal 
anti-Hsp47 antibodies (Enzo Life Sciences) and mouse 
IgG2b (isotype control) were applied (2 μg/ml) over night 
at 4°C. Slides were washed in TBS-T and incubated with 
biotinylated goat anti-mouse antibodies (Dako). The signal 
was amplified with horseradish peroxidase-conjugated 
streptavidin (Nichirei Bioscience) and detected with 
3,3′-diaminobenzidine. Cartilage destruction was scored 
from 0 (no cartilage loss) to 3 (complete loss of articular 
cartilage) [43]. The Hsp47-positive lining area was adjusted 
to the linear horizontal length (μm2/μm) of the analyzed 
lining [12]. 
statistical analysis
Mean ± SD values were calculated. Unpaired or 
paired t-tests were used for statistical evaluation of the 
data using GraphPad Prism 5.0. P values less than 0.05 
were considered significant. The fit of regression model 
was assessed by coefficient of determination.
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